Benzinga | Sep 21, 2021 10:06AM EDT

Hoth Therapeutics Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In BioLexa Clinical Trial

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing patients with mild to moderate atopic dermatitis, also known as eczema. There were no serious adverse events and no drug-related treatment-emergent adverse events observed during the administration of BioLexa in healthy subjects. Based on the recommendations of the SRC, Hoth has submitted to the Human Research Ethics Committee (HREC) overseeing the trial to obtain official approval to proceed dosing the patient cohort. The official submission to HREC occurred on September 10, 2021.

"This second submission to HREC is a welcome next step in our continued investigation of BioLexa," stated Robb Knie, CEO of Hoth Therapeutics. "We look forward to receiving swift HREC approval to advance our trial in patients living with mild to moderate eczema."

Additional information and updates on the BioLexa clinical trial can be found by visiting www.hoththerapeutics.com and https://clinicaltrials.gov.